Trial Profile
A randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with Bortezomib
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Mar 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms REMoDL-B
- 13 Dec 2022 Results (n=67) assessing the impact of R-CHOP on QoL in patients enrolled in the control arm of the study, with 5 years of follow-up, presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 01 Apr 2019 Results evaluating outcomes of adding bortezomib to standard therapy in patients with diffuse large B-cell lymphoma published in the Lancet Oncology
- 03 Dec 2018 Results of retrospective study from patients (n=928) treated in REMoDL-B trial, published in the Journal of Clinical Oncology.